It is very important that pharmacists effectively counsel patients on titration schedules and recognize and support the treatment expectations and goals of the patient
Marek focuses on hormone optimization with lab-driven protocols and partner clinicians - Marek is generally more expensive and expects lab testing - Not a direct substitute for a weight-loss-only GLP-1 subscription - See Marek Health reviews Pomegranate Health vs LillyDirect or Novo self-pay: - LillyDirect sells Zepbound to self-pay patients at ~$350-$550/month for FDA-approved product - Novo self-pay options for Wegovy and Ozempic are more limited but expanding - Brand products have published stability, standardized manufacturing, and no compounding regulatory question - Increasingly the default for patients without insurance coverage - See where to buy tirzepatide Pomegranate Health vs a local compounding pharmacy: - Bypasses the telehealth middleman and subscription layer - Requires you to find a PCAB-accredited local compounding pharmacy that can serve you - Usually cheaper per month once the setup is complete, but requires more self-advocacy and often an in-person prescriber - Not practical for patients without a clinician willing to write the prescription The rule of thumb: for most patients, if insurance covers brand GLP-1 use the brand
The loophole is Section 503B of the Federal Food, Drug, and Cosmetic Act, which enables compounding facilities to produce knockoff versions of drugs that are in shortage
(A) GLP-1 can induce fibronectin type III domain-containing protein 5 (FNDC5) expression in pancreatic -cells through the interaction of its downstream transcription factor cAMP-response element binding protein (CREB) with binding elements in the FNDC5 promoter, thereby promoting the conversion of white adipose tissue (WAT) to brown adipose tissue (BAT)
Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus
For those initiating GLP-1 therapy in 2021, 33% were persistent, while in the first quarter of 2024, 63% of new initiators were persistent
